Atopic Dermatitis Drugs Market by Route Of Administration, Drug Class, and Geography - Forecast and Analysis 2023-2027

Published: Apr 2023 Pages: 162 SKU: IRTNTR75242

The atopic dermatitis drugs market size is estimated to grow at a CAGR of 9.28% between 2022 and 2027. The market size is forecast to increase by USD 4,720.19 million. The growth of the market depends on several factors, including the high prevalence of atopic dermatitis, the increasing healthcare expenditure, and the strong R&D pipeline.

This atopic dermatitis drugs market report extensively covers market segmentation by route of administration (oral, topical, and injectable), drug class (biologics, PDE4 inhibitors, corticosteroids, and calcineurin inhibitors), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the Size of the Atopic Dermatitis Drugs Market During the Forecast Period?

To learn more about this report, View Report Sample

Atopic Dermatitis Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The high prevalence of atopic dermatitis is notably driving the market growth, although factors such as the loss of patents and patent expiry may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Atopic Dermatitis Drugs Market Driver

The high prevalence of atopic dermatitis is the key factor driving the growth of the global atopic dermatitis drugs market. The prevalence of atopic dermatitis is high worldwide. Atopic dermatitis can be caused or exacerbated by several factors, including exposure to allergens such as peanuts, pollen, and animal danger. skin irritants such as household cleaners; certain fabrics or soaps; stress, dry skin, and infections. In the United States alone, approximately 18 million people currently have atopic dermatitis. In the United States, an estimated 9 million to 10 million of her children under the age of 18 suffer from atopic dermatitis, about one-third of whom have moderate to severe disease. Such a large patient pool represents a huge opportunity for the growth of the global atopic dermatitis therapeutics market.

A large patient cohort requires multiple visits to a dermatologist and the use of numerous medications to treat atopic dermatitis, thus driving the market growth. Asia also hosts a huge patient population with atopic dermatitis, with China, India, and Japan being the top three revenue contributors to the market in the region. Developing countries, such as India and China, present promising market opportunities due to their large population base. According to The World Bank Group, the population of China was 1.42 billion in 2021, while that of India was 1.41 billion in the same year. Therefore, the high prevalence of atopic dermatitis is expected to drive the growth of the global atopic dermatitis drugs market during the forecast period.

Significant Atopic Dermatitis Drugs Market Trends

The geopolitical uncertainties are the primary trend shaping the global atopic dermatitis drugs market. Trade policy uncertainty between nations creates an unfavorable environment for suppliers regarding investment decisions and long-term growth strategies. For instance, the pharmaceutical landscape is changing rapidly in China, with the presence of large American pharmaceutical corporations such as Pfizer, which has invested over USD 1.5 billion in the country so far. However, the trade dispute between the United States and China has adversely affected the operations of many such drug makers. This standoff has adversely affected the import of eczema medications from China into the United States.

China responded to the aggressive trade policies of the US by increasing the tariff on the imports of atopic dermatitis drugs from China. The ongoing trade war has become a major concern for manufacturers and suppliers engaged in the trade of raw materials, active pharmaceutical ingredients (API), as well as finished drugs in both countries, as they are being taxed at multiple points in the supply chain, which is adversely affecting their revenues. Such uncertainties triggered by bilateral disagreements may negatively impact the growth of the global atopic dermatitis drugs market during the forecast period.

Major Atopic Dermatitis Drugs Market Challenge

Loss of patents and patent expiry is a major challenge to the growth of the global atopic dermatitis drugs market. Loss or revocation of patents poses a significant threat to large companies that own their own patents. Ultimately, the loss or expiration of patents tends to flood the market with generic drugs, losing competitive advantage and margins for large companies. Generic medicines are medicines that are similar in quality, dosage form, strength, and potency to branded medicines but are available at a lower price. Due to the low-price availability of these generic drugs, increasing penetration of generic drugs will limit the market growth.

Allegations associated with the infringement of patents and other intellectual property rights by third parties affect the business of a pharmaceutical company. The expiry of the patent on branded atopic dermatitis drugs will result in the proliferation of generic drugs in the market, thus reducing the sales of branded drugs, which can negatively affect the business of prominent vendors. Thus, this will hinder revenue growth prospects in the market in focus during the forecast period.

Key Atopic Dermatitis Drugs Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Atopic Dermatitis Drugs Market Customer Landscape

Who are the Major Atopic Dermatitis Drugs Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc.: The company offers atopic dermatitis drugs such as RINVOQ. Also, the company conducts research and development, manufacturing, commercialization and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis to achieve established long-term strategic goals.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Arcutis Biotherapeutics Inc.
  • Asana BioSciences LLC
  • Astellas Pharma Inc.
  • Bausch Health Co. Inc.
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Dermavant Sciences Inc.
  • Eli Lilly and Co.
  • Evelo Biosciences Inc.
  • Galderma SA
  • Incyte Corp.
  • LEO Pharma AS
  • Maruho Co. Ltd.
  • Novartis AG
  • Otsuka Holdings Co. Ltd.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Atopic Dermatitis Drugs Market?

The market share growth by the oral segment will be significant during the forecast period. Factors such as, the rising number of approvals of various oral drugs for atopic dermatitis and their benefits, such as ease of use, are expected to drive the segment growth, which in turn, is anticipated to propel the growth of the market in focus during the forecast period.

Get a glance at the market contribution of various segments View the PDF Sample

The oral segment was valued at USD 2,267.71 million in 2017 and continued to grow until 2021. Easy-to-use benefits of drugs that are taken via the oral route and the growing popularity of prescription-based drugs, such as oral capsules, are driving the growth of the oral segment during the forecast period. For instance, in January 2022, AbbVie and Pfizer received approval for Upadacitinib and Abrocitinib from the US FDA for the treatment of refractory moderate to severe atopic dermatitis. Such developments are likely to propel the growth of the oral segment during the forecast period.

Which are the Key Regions for the Atopic Dermatitis Drugs Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Among all regions, North America accounted for the largest share of the global atopic dermatitis drug market in 2022. This is due to factors such as the high level of awareness of health care, and the presence of an established medical infrastructure in the region. In addition, the market is expected to show promising growth over the forecast period owing to favorable reimbursement policies, a rising number of drug approvals in the US, and rising healthcare costs. For instance, in the US, national healthcare spending grew by 2.7% in 2021 over 2020 and reached USD 4.3 trillion or USD 12,914 per person. Thus, the growing expenditure associated with healthcare is likely to increase the demand for atopic dermatitis drugs among patients in the region. 

The outbreak of COVID-19 affected all countries in North America, especially the US, in 2020. However, by the second quarter of 2021, restrictions were mostly relaxed due to the implementation of mass COVID-19 vaccination in various countries, which led to the resumption of approval processes and the manufacturing of vital drugs, including for the treatment of atopic dermatitis. Such factors will increase the market growth during the forecast period.

Segment Overview

The atopic dermatitis drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Route of Administration Outlook (USD Million, 2017 - 2027)
    • Oral
    • Topical
    • Injectable
  • Drug Class Outlook (USD Million, 2017 - 2027)
    • Biologics
    • PDE4 inhibitors
    • Corticosteroids
    • Calcineurin inhibitors
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Australia
      • Argentina
      • Brazil

Parent Market Analysis

Technavio categorizes the global atopic dermatitis drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent, the global pharmaceuticals, market covers products and companies engaged in R&D or the production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.

Atopic Dermatitis Drugs Market Scope

Report Coverage

Details

Page number

162

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 9.28%

Market growth 2023-2027

USD 4,720.19 million

Market structure

Fragmented

YoY growth 2022-2023(%)

8.68

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 36%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading vendors, market positioning of vendors, competitive strategies, and industry risks

Key companies profiled

AbbVie Inc., Arcutis Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Co. Inc., Bayer AG, Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Viatris Inc., and BiomX Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View the PDF sample

What are the Key Data Covered in this Atopic Dermatitis Drugs Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the atopic dermatitis drugs market between 2023 and 2027
  • Precise estimation of the size of the atopic dermatitis drugs market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of atopic dermatitis drugs market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global atopic dermatitis drugs market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on global atopic dermatitis drugs market 2017 - 2021 ($ million)
    • 4.2 Route of Administration Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Route of Administration Segment 2017 - 2021 ($ million)
    • 4.3 Drug Class Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Drug Class Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Route of Administration

    • 6.1 Market segments
      • Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
    • 6.2 Comparison by Route of Administration
      • Exhibit 32: Chart on Comparison by Route of Administration
      • Exhibit 33: Data Table on Comparison by Route of Administration
    • 6.3 Oral - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
    • 6.4 Topical - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Topical - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Topical - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Topical - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Topical - Year-over-year growth 2022-2027 (%)
    • 6.5 Injectable - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Injectable - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Injectable - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Injectable - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Injectable - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Route of Administration
      • Exhibit 46: Market opportunity by Route of Administration ($ million)
      • Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)

    7 Market Segmentation by Drug Class

    • 7.1 Market segments
      • Exhibit 48: Chart on Drug Class - Market share 2022-2027 (%)
      • Exhibit 49: Data Table on Drug Class - Market share 2022-2027 (%)
    • 7.2 Comparison by Drug Class
      • Exhibit 50: Chart on Comparison by Drug Class
      • Exhibit 51: Data Table on Comparison by Drug Class
    • 7.3 Biologics - Market size and forecast 2022-2027
      • Exhibit 52: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 54: Chart on Biologics - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
    • 7.4 PDE4 inhibitors - Market size and forecast 2022-2027
      • Exhibit 56: Chart on PDE4 inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Data Table on PDE4 inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 58: Chart on PDE4 inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on PDE4 inhibitors - Year-over-year growth 2022-2027 (%)
    • 7.5 Corticosteroids - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Corticosteroids - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Data Table on Corticosteroids - Market size and forecast 2022-2027 ($ million)
      • Exhibit 62: Chart on Corticosteroids - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Corticosteroids - Year-over-year growth 2022-2027 (%)
    • 7.6 Calcineurin inhibitors - Market size and forecast 2022-2027
      • Exhibit 64: Chart on Calcineurin inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Data Table on Calcineurin inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 66: Chart on Calcineurin inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 67: Data Table on Calcineurin inhibitors - Year-over-year growth 2022-2027 (%)
    • 7.7 Market opportunity by Drug Class
      • Exhibit 68: Market opportunity by Drug Class ($ million)
      • Exhibit 69: Data Table on Market opportunity by Drug Class ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 71: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 73: Chart on Geographic comparison
      • Exhibit 74: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Canada - Market size and forecast 2022-2027
      • Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 UK - Market size and forecast 2022-2027
      • Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.11 China - Market size and forecast 2022-2027
      • Exhibit 107: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 108: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 109: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 110: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 111: Market opportunity by geography ($ million)
      • Exhibit 112: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 113: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 115: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 116: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 117: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 118: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 119: AbbVie Inc. - Overview
              • Exhibit 120: AbbVie Inc. - Product / Service
              • Exhibit 121: AbbVie Inc. - Key news
              • Exhibit 122: AbbVie Inc. - Key offerings
            • 12.4 Arcutis Biotherapeutics Inc.
              • Exhibit 123: Arcutis Biotherapeutics Inc. - Overview
              • Exhibit 124: Arcutis Biotherapeutics Inc. - Product / Service
              • Exhibit 125: Arcutis Biotherapeutics Inc. - Key offerings
            • 12.5 Bausch Health Co. Inc.
              • Exhibit 126: Bausch Health Co. Inc. - Overview
              • Exhibit 127: Bausch Health Co. Inc. - Business segments
              • Exhibit 128: Bausch Health Co. Inc. - Key news
              • Exhibit 129: Bausch Health Co. Inc. - Key offerings
              • Exhibit 130: Bausch Health Co. Inc. - Segment focus
            • 12.6 Bristol Myers Squibb Co.
              • Exhibit 131: Bristol Myers Squibb Co. - Overview
              • Exhibit 132: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 133: Bristol Myers Squibb Co. - Key news
              • Exhibit 134: Bristol Myers Squibb Co. - Key offerings
            • 12.7 Eli Lilly and Co.
              • Exhibit 135: Eli Lilly and Co. - Overview
              • Exhibit 136: Eli Lilly and Co. - Product / Service
              • Exhibit 137: Eli Lilly and Co. - Key offerings
            • 12.8 Evelo Biosciences Inc.
              • Exhibit 138: Evelo Biosciences Inc. - Overview
              • Exhibit 139: Evelo Biosciences Inc. - Product / Service
              • Exhibit 140: Evelo Biosciences Inc. - Key offerings
            • 12.9 Galderma SA
              • Exhibit 141: Galderma SA - Overview
              • Exhibit 142: Galderma SA - Product / Service
              • Exhibit 143: Galderma SA - Key news
              • Exhibit 144: Galderma SA - Key offerings
            • 12.10 Incyte Corp.
              • Exhibit 145: Incyte Corp. - Overview
              • Exhibit 146: Incyte Corp. - Product / Service
              • Exhibit 147: Incyte Corp. - Key offerings
            • 12.11 LEO Pharma AS
              • Exhibit 148: LEO Pharma AS - Overview
              • Exhibit 149: LEO Pharma AS - Business segments
              • Exhibit 150: LEO Pharma AS - Key offerings
              • Exhibit 151: LEO Pharma AS - Segment focus
            • 12.12 Maruho Co. Ltd.
              • Exhibit 152: Maruho Co. Ltd. - Overview
              • Exhibit 153: Maruho Co. Ltd. - Product / Service
              • Exhibit 154: Maruho Co. Ltd. - Key offerings
            • 12.13 Novartis AG
              • Exhibit 155: Novartis AG - Overview
              • Exhibit 156: Novartis AG - Business segments
              • Exhibit 157: Novartis AG - Key offerings
              • Exhibit 158: Novartis AG - Segment focus
            • 12.14 Otsuka Holdings Co. Ltd.
              • Exhibit 159: Otsuka Holdings Co. Ltd. - Overview
              • Exhibit 160: Otsuka Holdings Co. Ltd. - Business segments
              • Exhibit 161: Otsuka Holdings Co. Ltd. - Key offerings
              • Exhibit 162: Otsuka Holdings Co. Ltd. - Segment focus
            • 12.15 Pfizer Inc.
              • Exhibit 163: Pfizer Inc. - Overview
              • Exhibit 164: Pfizer Inc. - Product / Service
              • Exhibit 165: Pfizer Inc. - Key news
              • Exhibit 166: Pfizer Inc. - Key offerings
            • 12.16 Sanofi SA
              • Exhibit 167: Sanofi SA - Overview
              • Exhibit 168: Sanofi SA - Business segments
              • Exhibit 169: Sanofi SA - Key news
              • Exhibit 170: Sanofi SA - Key offerings
              • Exhibit 171: Sanofi SA - Segment focus
            • 12.17 Viatris Inc.
              • Exhibit 172: Viatris Inc. - Overview
              • Exhibit 173: Viatris Inc. - Business segments
              • Exhibit 174: Viatris Inc. - Key offerings
              • Exhibit 175: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 176: Inclusions checklist
                • Exhibit 177: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 178: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 179: Research methodology
                • Exhibit 180: Validation techniques employed for market sizing
                • Exhibit 181: Information sources
              • 13.5 List of abbreviations
                • Exhibit 182: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              atopic dermatitis drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis